摘要:
The invention concerns the use of Ginkgo biloba extracts, and in particular Ginkgo biloba extracts containing 20 to 30 % of flavoneglycosides, 2.5 to 4.5 % of ginkgolides A, B, C and J, 2 to 4 % of bilobalide, less than 10 % of proanthocyanidines and less than 10 ppm of compounds of the alkylphenol type, for preparing a medicine for treating amyotrophic lateral sclerosis.
摘要:
The invention concerns novel compounds having the elements of group 11, 12 or 14 and a tridentate ligand, a method for preparing them and their use in particular as polymerisation catalyst.
摘要:
The present invention is directed to a method of establishing an 'identity' of Ginkgo biloba leaves or isolated ginkgolide B (GKB) or another component of the extract of Ginkgo biloba leaves, by obtaining a 'gene regulation profile'. The invention is also directed to a method of verifying the identity of a Ginkgo biloba extract by comparing the gene regulation profile of a Gingko biloba extract of unknown or questionable origin with the gene regulation pofile of a Gingko biloba extract of known origin. The present invention is further directed to a method of establishing a gene expression profile of Ginkgolide A, Ginkgolide B or any other component isolated from a Ginkgo biloba extract, more particularly, from EGB 761®.
摘要:
The invention concerns crosslinked copolymers based on non-crosslinked polycarboxylic copolymers, said non-crosslinked copolymers containing at least a polysaccharide. The invention also concerns a method for preparing said copolymers and their use in particular as support in pharmaceutical compositions.
摘要:
The invention concerns a product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance, separately or combined, for simultaneous therapeutic use, separately or spread over time for treating pathologies in which nitrogen monoxide and/or phosplipases A2 are involved. The invention also concerns a pharmaceutical composition comprising, as active principle, at least a NO synthase inhibiting substance and at least a phospholipase A2 inhibiting substance, and optionally a pharmaceutically acceptable carrier.
摘要:
The invention concerns nucleic acids coding for peptides having the biological activity of sorbin, the resulting coded peptides and their therapeutic uses, particularly the use of their properties on water and electrolyte cell absorption.
摘要:
The invention concerns the use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from prenylation of the η subunit of G protein. Said diseases comprise in particular diseases related to the following biological functions or disorders: smell, taste, light perception, neurotransmission, neurodegeneration, endocrine and exocrine gland functioning, autocrine and paracrine regulation, blood pressure, embryogenesis, viral infection, immunological functions, diabetes and obesity.
摘要:
The invention concerns novel solid or semi-solid pharmaceutical compositions comprising a soluble peptide salt capable of jellifying, having a high specific surface area. Said compositions can also comprise an excipient and/or water. Once injected to a patient, the compositions jellify and release the peptide salt for a long time interval not less than 15 days.
摘要:
The invention concerns novel camptothecin analogues and in particular products corresponding to the following formulae: (+)-5-ethyl-9, 10-difluoro-5-hydroxy-4, 5,13,15-tetrahydro-1H, 3H-oxepino[3',4':6, 7]indolizino[1,2-b] quinoline-3,15-dione; (+)-1-[9-chloro-5- ethyl-5-hydroxy-10-methyl-3, 15-dioxo-4,5,13, 15-tetrahydro-1H,3H-oxepinol[3' ,4':6,7]indolizino [1,2-b]quinoline-12-ylmethyl] -4-methyl-hexahydropyridinium chloride; their application as medicine, pharmaceutical compositions containing them and their use for producing antitumoral, antiviral or antiparasitic medicines. The invention also concerns a novel synthesis intermediate of said products and a method for preparing said intermediate.
摘要:
The invention concerns novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions containing them. It also discloses a method for preparing said derivatives. In formula (I), W, X, Y and Z represent independently the radicals H, OH, linear or branched alkoxy or O-GS, GS-OH representing mono- or disaccharide, or one of their derivatives or analogs, with the proviso that at least one of W, X, Y or Z is a O-GS radical.